To the federal government, psychedelic drugs like LSD, MDMA (also known as Ecstasy or Molly in its street forms), and psilocybin (the psychoactive ingredient in mushrooms) are dangerous Schedule I substances with a high potential for abuse and no medical value.
But leading psychedelic researchers paint a much different picture one of fascinating compounds with the power to rewire the human brain and possibly revolutionize treatment for a number of debilitating mental health issues.
Weve yet to find a conclusive answer that can prove either side right or wrong, though initial indications suggest its fair to be skeptical of the U.S. Drug Enforcement Administrations view. Early clinical studies have produced promising results, convincing many that psychedelics are at least worthy of further research. But thanks to a grueling approval process and the widespread stigma attached to these drugs, the path to officially recognizing their potential medical benefits has been difficult.
A crowdfunding initiative launched Tuesday gives the public a chance to help accelerate this process by donating directly to psychedelic science.
The Fundamental campaign has partnered with experts in the field of psychedelic research in hopes of raising$2 million over the next four months. Donated money will be split between four areas. Two studies involve psilocybin-assisted psychotherapy, with one focused on the treatment of end-of-life anxiety and the other on alcoholism.A third study is examining the use of MDMA-assisted psychotherapy to treat post-traumatic stress disorder. The fourth is looking at the effects of LSD-microdosing therapies, which have been touted as a way to enhance mood, cognition, productivity and creativity.
New York real estate developer Rodrigo Nio is heading up Fundamental, drawing from his personal experience in the fields of both crowdfunding and psychedelic therapy.
In May 2011, Nio realized he had an unusual skin growth. He saw a doctor, and days later received a devastating diagnosis: At 41, Nio had stage 3 melanoma. His odds of survival were 1 in 3 over the next five years.
Nio underwent a pair of procedures in the following months to remove cancerous growths, but he remained haunted by anxiety that the disease would kill him. In the summer of 2011,Nio traveled to the Peruvian Amazon, where he partook in a number of ayahuasca ceremonies over the next few weeks. He returned home completely changed.
I got completely over my fear of dying, Nio told HuffPost.
Although the ayahuasca felt like a miracle cure for his anxiety, Nio wasnt sure if his newfound sense of calm was a placebo effect, or if the psychedelic jungle vine had actually altered his brain chemistry.
Back in New York,Nio met with Stephen Ross,director of addiction psychiatry at NYU Langone Medical Center, who explained to him that psilocybin a psychoactive ingredient different from the one found in ayahuasca had begun to show promising results as a treatment for end-of-life anxiety. Over the next few years, Nios interest in the therapeutic applications of psychedelic drugs grew, as did the body of scientific research.
This past December, Ross and researchers at Johns Hopkins Universitypublished the results of two separate clinical trials on the effects of psilocybin-assisted psychotherapy on patients with cancer-related anxiety and depression. All told,between 60 and 80 percent of the subjects showed clinically significant reductions in both psychological disorders after treatment. Patients reported that the benefits of a single dose of psilocybin along with therapy lasted up to seven months, with minimal side effects.
Now, Fundamental is hoping to provide Ross with the money to explore this preliminary research in the kind of large-scale trials necessary to better understand the therapeutic value of psilocybin.
The problem with funding for psychedelic research is its incredibly hard to do, Ross explains in a video for Fundamental. The federal government will give approval through the [Food and Drug Administration]and the DEA, but the [National Institutes of Health]agencies dont appear yet ready to fund psychedelic research.
Fundamental is also raising money for research on the effects of psilocybin-assisted treatment on alcoholism, which Michael Bogenschutz at NYU Langone is heading up. Initial studieshave shown promise, building on a rich history of anecdotal evidence that psychedelic drugs could help people battle addiction.
If we had more funding, we could accelerate the rate of the research, we could accelerate potential discoveries and breakthroughs, and we could accelerate the rate at which these medicines may become available to alleviate human suffering, Ross says in the video.
Part of the challenge in financing psychedelic research is that theres no profit motive for large pharmaceutical companies, Nio says. These studies dont focus on treating symptoms. Rather, theyre trying to address the root cause of mental illness by essentially disrupting the default mode network, or ego, of a persons brain. In other words, theyre trying to eliminate the need for treatment, not offer an ongoing one.
The problem is that these natural compounds sometimes require only two sessions to do what a lifetime of treatment wouldnt do with traditional antidepressants, Nio told HuffPost. They dont really make money, because theyre also in the public domain and they cant be patented.
But Nio hopes that Fundamental can help create a movement around the issue of psychedelic research and therapy.
Were trying to inspire people to realize that despite the fact this doesnt make money, its something that must happen for the sake of everybody, he said.
Fundamental has also partnered with Rick Doblin, executive director of the Multidisciplinary Association for Psychedelic Studies, which isbeginning phase three clinical trialson MDMA as a treatment for PTSD. Phase three is the final step before a medication can officially be approved by the FDA as a prescription drug a goal MAPS is hoping to reach by 2021.
Early studies on MDMA and PTSD have produced impressive results, with one trial showing nearly 70 percent effectivenessin reducing symptoms after a handful of sessions of MDMA-assisted therapy.
For Fundamentals fourth initiative, the campaign has joined forces with psychedelic pioneer Amanda Feilding to look into the science of microdosing with LSD a pursuit thats become popular in recent years, especially in the fast-paced world of Silicon Valley.
Feilding is the founder and director of the Beckley Foundation, a think tank that advocates for psychedelic research.Her latest project seeks to gain a better understanding of how small amounts of LSD can affect human performance and brain function. Feildings study involves doing brain imaging on a small number of subjects while they engage in a variety of cognitive tasks. Participants will also play the ancient Chinese board game Go against a computer.Feilding hopes this will allow her to examine how LSD changes brain connectivity and contributes to enhanced creativity or problem-solving skills.
If all of this research seems a bit, well, out there, thats not unreasonable. Nio says its fair to be skeptical and its critical to proceed with caution, which is exactly why rigorous scientific studies like these are needed.
We think that psychedelics dont create addiction based on the evidence, but we need to confirm it, he said. We think that it will help with depression and end-of-life anxiety and so on and so forth, but we need to scientifically confirm it as well.
And though Nio suggested these studies could help break the stigma surrounding psychedelics, perhaps even putting them on the road to legalization, he said that was far beyond the scope of the Fundamental campaign.
This is not an invitation to do illicit drugs of any sort, Nio said. This is an invitation to collectively back up the researchers who are finding out whether this has potential or not, as the evidence is showing it does on a preliminary basis.
Fundamental is collecting money through the website CrowdRise. Donations will be deposited into an account controlled by a third-party group,Charity Aid Foundations of America. When the campaign closes on Sept. 9, the money will be distributed as grants among the different research programs.
- Researchers went to festivals to study psychedelic drugs and found they left people feeling happy and connected hours after the high wore off -... - January 22nd, 2020
- Psychedelics and Their 'Mystical Effects' in the Real World - Medscape - January 22nd, 2020
- Psychedelic Events Are Going Mainstream, Where The Much-Maligned Mushroom Industry Focuses On Mental Health - Forbes - January 18th, 2020
- Psychedelics have 'extraordinarily potent' anti-inflammatory power. Is there a place for them in mainstream medicine? - Genetic Literacy Project - January 18th, 2020
- Silicon Valley Is Micro-Dosing Magic Mushrooms To Boost Their Careers - Forbes - January 18th, 2020
- NYC To Host Economics Of Psychedelics Investing Summit - Benzinga - January 18th, 2020
- The Best FREE Things to Do for the Next Week - My New Orleans - January 18th, 2020
- Photos of the Stuff That Fascinates People While They're Tripping On LSD - VICE - January 18th, 2020
- Rats on DMT hint at the benefits of psychedelic microdosing - Inverse - December 31st, 2019
- BEYOND LOCAL: Would you ever consider psychedelics to treat PTSD? - SooToday.com - December 31st, 2019
- A Trailblazer of Global Consciousness: Ram Dass Led the Way - Psychology Today - December 31st, 2019
- The Psychedelic Renaissance and the importance of drug policy reform - Open Access Government - December 13th, 2019
- Magic Mushrooms Move Closer to Mainstream Medicine As VC-Backed Compass Touts Safety, Positive Mood Alteration - Karma - December 13th, 2019
- Miami Clinics Use Ketamine IV Therapy to Help Treat Depression and PTSD - Miami New Times - December 13th, 2019
- Andy Frasco Talks Finding Emotional Balance With Psychedelics On 'Psychedelics Today' Podcast [Listen] - Live for Live Music - November 30th, 2019
- Will psychedelics be available commonly in the near future? - BPhrm Dv - November 30th, 2019
- Letters to the Editor: Psychedelics on their way - Valley Advocate - November 30th, 2019
- Scientists Have a Fascinating New Map of the Human Brain on DMT - VICE - November 30th, 2019
- Hes a fungi: U.S. health agency asks researcher to give it the lowdown on psilocybin mushrooms - The GrowthOp - November 30th, 2019
- A Magic Mushroom Test Case, and the Man Behind It - OZY - November 30th, 2019
- The Two Black Women Helping To Reclaim & Encourage Natural Psychedelics Use In Oakland - Okayplayer - November 2nd, 2019
- Molecule Catalyst and UTM to crowdfund psychedelics research with blockchain - Decrypt - November 2nd, 2019
- On writing: What illuminates a story? - Big Think - November 2nd, 2019
- The future of psychedelic science - Varsity - October 20th, 2019
- Psychedelic Drugs: Researchers experimenting with active agent in magic mushrooms to treat addiction, depression and anxiety - 60 Minutes - CBS News - October 17th, 2019
- Investors hope psychedelics are the new cannabis. Are they high? - The Economist - October 17th, 2019
- Mind Trip: Psychedelics Fighting Depression, Anxiety, Addiction - The National Herald - October 17th, 2019
- Devon Welsh on Growing a Mustache, Psychedelics, and Other Complicated Things - Interview - October 17th, 2019
- Roland Griffiths: 5 Fast Facts You Need to Know - Heavy.com - October 17th, 2019
- How Mushrooms Became Magic - The Atlantic - August 25th, 2017
- Using Mushrooms and LSD to Enhance Creativity - How to Use ... - August 20th, 2017
- LSD - Psychedelics - August 16th, 2017
- This Philosopher Thinks Psychedelic Drugs Lead to the Truth of Experience - Big Think - August 16th, 2017
- Can Psychedelics Treat Bipolar Disorder? - August 13th, 2017
- The foundation of Western philosophy is probably rooted in psychedelics - Quartz - August 13th, 2017
- Psychedelic drugs saved my life. So why aren't they prescribed? - Wired.co.uk - August 8th, 2017
- Daniel Greig, Canadian Drug Policy, Responsibilities, and Psychedelics - The Good Men Project (blog) - August 6th, 2017
- THE FUTURE OF PSYCHEDELICS: Are LSD and Mushrooms The New Prozac? - Dope Magazine - August 5th, 2017
- Gonzo Nieto, Drug Policy, Medical and Psychological Effects - The Good Men Project (blog) - August 3rd, 2017
- For children, it's beyond psychedelics - The Hans India - The Hans India - August 1st, 2017
- Modern psychedelic science is reviving lost research and finding new cures - The Plaid Zebra (blog) - August 1st, 2017
- Expanding consciousness - 48 Hills - August 1st, 2017
- What Has Awe Done for Me Lately? - HuffPost - July 31st, 2017
- New book about psychedelics and weird human experiences - Boing Boing - July 26th, 2017
- Psychedelics and Normality - HuffPost - July 26th, 2017
- Reasons to Consider Trying Psychedelics - FoxWeekly - July 25th, 2017
- Psychedelic Shine takes a trip to the skies in Boulder - Boulder Daily Camera - July 22nd, 2017
- Psychedelic drugs could tackle depression in a way that antidepressants can't - INSIDER - July 22nd, 2017
- Do You Take Drugs at Festivals? This Initiative is Working on Keeping You Safe - PoliticalCritique.org - July 20th, 2017
- Should We Reclassify Marijuana as a Hallucinogen? - Big Think - July 20th, 2017
- Countdown To (Legalized) Ecstasy! Rick Doblin, MAPS, & the Psychedelic Renaissance [Podcast] - Reason (blog) - July 20th, 2017
- Can Psychedelics Be Therapy? Allow Research to Find Out - New York Times - July 18th, 2017
- Psychiatrists Say Cannabis Medicine Has Psychedelic Properties - The Marijuana Times - July 15th, 2017
- Are psychedelics the new medical marijuana? - WTSP 10 News - July 13th, 2017
- Alameda author's new book examines psychedelic drugs' medical use - East Bay Times - July 12th, 2017
- Do Psychedelic Drugs Cause the 'Prophetic Effect'? - Breaking Israel ... - Breaking Israel News - July 11th, 2017
- Shrooms Could Be Legalized Sooner Than You Think - VICE - July 11th, 2017
- Parliament George and the Psychedelics? Mayor gets playful lesson on hipness - The Telegraph (blog) - July 8th, 2017
- About Us | Trusted News Source for Psychedelic Research ... - July 7th, 2017
- My grandfather was a death row doctor. He tested psychedelic drugs on Texas inmates. - Texas Tribune - July 5th, 2017
- Psychedelics Could Help Asia's Mental Health Care, But Stigma Remains Roadblock - TheFix.com - July 4th, 2017
- Is LSD the new coffee? - FactorDaily - July 4th, 2017
- Tune in, Turn on, Stay in School - Study Breaks - July 2nd, 2017
- The brain on DMT: mapping the psychedelic drug's effects - Wired.co.uk - July 2nd, 2017
- Cannabist Show: He's psychedelic comedian Shane Mauss - The Cannabist - July 1st, 2017
- The war on drugs is back. Will psychedelic drug research survive? - The Verge - June 29th, 2017
- Psychedelics and Virtual Reality Make a Trendy but Illegal Therapy - Inverse - June 27th, 2017
- Director Ana Lily Amirpour on Cannibalism, Psychedelics, and 'Horrifying' Racism Allegations - Jezebel - June 24th, 2017
- The Refugee Funding America's Psychedelic Renaissance - VICE - June 24th, 2017
- Majority of Americans ready to embrace psychedelic therapy - YouGov US - June 24th, 2017
- DISMANTLING THE DRUG WAR: Is Cannabis a Gateway to Legalizing Drugs? - Dope Magazine - June 24th, 2017
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - The Oakland Press - June 23rd, 2017
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - The Daily Tribune - June 22nd, 2017
- Shane Mauss brings Good Trip Comedy Tour to town - Chattanooga Times Free Press - June 22nd, 2017
- Q&A: LaughFest comedian talks science and psychedelics | Athfest ... - Red and Black - June 21st, 2017
- Q&A With Psychedelic Stand-Up and LaughFest Headliner Shane Mauss - Flagpole Magazine - June 19th, 2017
- What it's like to take psychedelics in small doses at breakfast | New ... - New Scientist - June 15th, 2017
- 'Changing Our Minds' explores psychedelic drugs and spiritual healing - Religion News Service - June 14th, 2017
- Cary Grant was one of the first to benefit from LSD therapy - Quartz - June 11th, 2017
- Stop Policing Psychedelic Science - Motherboard - June 6th, 2017